Lancaster General Health is a regional health system in Lancaster, Pennsylvania. It is part of the University of Pennsylvania Health System. Its flagship hospital is Lancaster General Hospital.

There are 631 beds in Lancaster General Health.

During the past decade, Lancaster General Health conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lancaster General Health" #1 sponsor was "Lancaster General Hospital" with 8 trials, followed by "Bristol-Myers Squibb" with 3 trials sponsored, "American Society of Clinical Oncology" with 1 trials sponsored, "Impulse Dynamics" with 1 trials sponsored and "Vixiar Medical, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lancaster General Health" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator, "Louise von Hess Medical Research Institute" with 1 trials as a collaborator and "Toshiba America Medical Systems, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Lancaster General Health" are "Cardiology" (2 trials), "Heart Failure" (2 trials), "Arthroplasty Complications" (1 trials), "Chronic Myeloid Leukemia" (1 trials) and "Concussion Post Syndrome" (1 trials). Many other conditions were trialed in "Lancaster General Health" in a lesser frequency.

Most popular intervention types in "Lancaster General Health" are "Device" (4 trials), "Drug" (3 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "CT-FFR and CTP" (1 trials), "Carboplatin" (1 trials), "Cisplatin" (1 trials) and "HEALiX" (1 trials). Other intervention names were less common.

The vast majority of trials in "Lancaster General Health" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Lancaster General Health". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 6 completed trials in Lancaster General Health, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Lancaster General Health, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".

Lancaster General Health has several departments that took part in Clinical trials: "Lancaster General Ann B Barshinger Cancer Institute" - 13 trials, "Heart Group" - 2 trials